Minerva Neurosciences Company Profile (NASDAQ:NERV)

About Minerva Neurosciences

Minerva Neurosciences logoMinerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio include MIN-101 for the treatment of schizophrenia; MIN-117 for the treatment of major depressive disorder (MDD); MIN-202 (also known as JNJ-42847922) for the treatment of insomnia disorder and adjunctive MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 blocks serotonin receptors and sigma receptors, over two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-HT1A. MIN-202 is a selective orexin 2 receptor antagonist it is developing in collaboration with Janssen Pharmaceutica NV. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 protein.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NERV
  • CUSIP:
Key Metrics:
  • Previous Close: $14.12
  • 50 Day Moving Average: $13.035
  • 200 Day Moving Average: $9.622
  • 52-Week Range: $3.45 - $15.84
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -12.83
  • P/E Growth: 0.000
  • Market Cap: $491.27M
  • Outstanding Shares: 34,805,000
  • Beta: 1.91
Profitability:
  • Return on Equity: -36.07%
  • Return on Assets: -26.70%
Debt:
  • Debt-to-Equity Ratio: 0.05%
  • Current Ratio: 15.64%
  • Quick Ratio: 15.64%
Additional Links:
Companies Related to Minerva Neurosciences:

Analyst Ratings

Consensus Ratings for Minerva Neurosciences (NASDAQ:NERV) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $17.00 (20.44% upside)
Analysts' Ratings History for Minerva Neurosciences (NASDAQ:NERV)
Show:
DateFirmActionRatingPrice TargetDetails
6/8/2016Jefferies GroupReiterated RatingBuy$17.00View Rating Details
5/26/2016JMP SecuritiesBoost Price Target$10.00 -> $17.00View Rating Details
1/22/2015Robert W. BairdSet Price TargetBuy$11.00View Rating Details
(Data available from 9/30/2014 forward)

Earnings

Earnings History for Minerva Neurosciences (NASDAQ:NERV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016        
8/4/2016Q116($0.30)($0.18)ViewListenView Earnings Details
5/3/2016Q1($0.33)($0.29)ViewListenView Earnings Details
3/14/2016Q4($0.31)($0.34)ViewListenView Earnings Details
11/5/2015Q315($0.36)($0.24)ViewListenView Earnings Details
8/5/2015Q215($0.41)($0.27)ViewN/AView Earnings Details
3/26/2015Q414($0.46)($0.40)ViewN/AView Earnings Details
11/10/2014($2.30)($1.53)ViewN/AView Earnings Details
8/7/2014Q2($0.38)($2.55)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Minerva Neurosciences (NASDAQ:NERV)
Current Year EPS Consensus Estimate: $-0.900 EPS
Next Year EPS Consensus Estimate: $-1.100 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.20)($0.20)($0.20)
Q3 20161($0.23)($0.23)($0.23)
Q4 20161($0.23)($0.23)($0.23)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Minerva Neurosciences (NASDAQ:NERV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Minerva Neurosciences (NASDAQ:NERV)
Insider Ownership Percentage: 28.10%
Institutional Ownership Percentage: 63.19%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/10/2016Venture Associates L Index IIIMajor ShareholderSell1,000,000$10.00$10,000,000.00View SEC Filing  
6/21/2016David KupferDirectorBuy55,635$10.84$603,083.40View SEC Filing  
3/17/2016David KupferDirectorBuy181,488$5.51$999,998.88View SEC Filing  
3/18/2015Care Capital Iii LlcMajor ShareholderSell1,206,700$5.75$6,938,525.00View SEC Filing  
3/18/2015Rubertis Francesco DeDirectorBuy202,634$4.81$974,669.54View SEC Filing  
3/13/2015& Johnson JohnsonMajor ShareholderBuy607,903$4.81$2,924,013.43View SEC Filing  
1/26/2015Care Capital Iii LlcMajor ShareholderSell482,112$5.11$2,463,592.32View SEC Filing  
1/8/2015Care Capital Iii LlcMajor ShareholderSell531,808$7.38$3,924,743.04View SEC Filing  
7/7/2014Care Capital Iii LlcMajor ShareholderBuy737,500$6.00$4,425,000.00View SEC Filing  
7/7/2014Michele OllierDirectorBuy1,620,833$6.00$9,724,998.00View SEC Filing  
7/1/2014Coelho Rogerio VivaldiCEOBuy41,667$6.00$250,002.00View SEC Filing  
7/1/2014Frederick W AhlholmCAOBuy10,000$6.00$60,000.00View SEC Filing  
7/1/2014Geoff RaceCFOBuy33,333$6.00$199,998.00View SEC Filing  
7/1/2014Heek G Jan VanDirectorBuy3,333$6.00$19,998.00View SEC Filing  
7/1/2014Joseph H ReillyInsiderBuy8,333$6.00$49,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Minerva Neurosciences (NASDAQ:NERV)
DateHeadline
News IconExpert Analysts Outlook for: Minerva Neurosciences, Inc (NASDAQ:NERV) , Stemline Therapeutics, Inc. (NASDAQ:STML) - Wall Street Times (press release) (NASDAQ:NERV)
www.wallstreetnews24.com - September 29 at 11:31 AM
News IconMinerva Neurosciences Provides Update On MIN-101 And MIN-117 Clinical Programs - Clinical Leader (NASDAQ:NERV)
www.clinicalleader.com - September 29 at 11:31 AM
News IconBroker Outlook For Minerva Neurosciences, Inc (NERV) - The De Soto Edge (NASDAQ:NERV)
desotoedge.com - September 29 at 11:31 AM
insidermonkey.com logoHere’s Why We’re Excited About The Upcoming Minerva Neurosciences Inc (NERV) Data (NASDAQ:NERV)
www.insidermonkey.com - September 28 at 11:21 AM
marketexclusive.com logoHere’s Why We’re Excited About THe Upcoming Minerva Neurosciences Inc (NASDAQ:NERV) Data (NASDAQ:NERV)
marketexclusive.com - September 27 at 6:13 PM
4-traders.com logoMinerva Neurosciences : Provides Update on MIN-101 and MIN-117 Clinical Programs (NASDAQ:NERV)
www.4-traders.com - September 27 at 10:57 AM
News IconSITO Mobile and Blue Bite Partner to Create Powerful Location-Based Targeting Tools with Real Time In-store Attribution (NASDAQ:NERV)
www.econotimes.com - September 26 at 6:25 PM
reuters.com logoBRIEF-Minerva Neurosciences provides update on clinical programs (NASDAQ:NERV)
www.reuters.com - September 26 at 6:25 PM
News IconStock Noted Gapping Up Pre-Market: Minerva Neurosciences, Inc. (NASDAQ:NERV) - Post News (NASDAQ:NERV)
www.kentuckypostnews.com - September 26 at 11:03 AM
nasdaq.com logoMinerva Neurosciences Provides Update on MIN-101 and MIN-117 Clinical Programs - Nasdaq (NASDAQ:NERV)
www.nasdaq.com - September 26 at 11:03 AM
biz.yahoo.com logoMINERVA NEUROSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:NERV)
biz.yahoo.com - September 26 at 11:03 AM
publicnow.com logoMinerva Neurosciences Provides Update on MIN-101 and MIN-117 Clinical Programs (NASDAQ:NERV)
www.publicnow.com - September 26 at 11:03 AM
News IconExpert Analysts Outlook for: Minerva Neurosciences, Inc (NASDAQ:NERV) , j2 Global, Inc. (NASDAQ:JCOM) - Wall Street Times (press release) (NASDAQ:NERV)
www.wallstreetnews24.com - September 25 at 5:42 PM
investornewswire.com logoShares Of Minerva Neurosciences, Inc (NASDAQ:NERV) Expected To Hit $17 - Investor Newswire (NASDAQ:NERV)
www.investornewswire.com - September 22 at 11:09 AM
finance.yahoo.com logoCan The Uptrend Continue for Minerva Neurosciences (NERV)? (NASDAQ:NERV)
finance.yahoo.com - September 21 at 10:29 AM
investing.com logoMinerva Neurosciences Inc: Resistance Breakout - Investing.com (NASDAQ:NERV)
www.investing.com - September 18 at 5:57 PM
investing.com logoMinerva Neurosciences Inc: Resistance Breakout (NASDAQ:NERV)
www.investing.com - September 18 at 10:41 AM
thestreet.com logo7 Stocks Making Big Moves With Unusual Volume (NASDAQ:NERV)
www.thestreet.com - September 16 at 9:53 AM
News IconNew Broker Views On Minerva Neurosciences, Inc (NERV ... - National Daily Press (NASDAQ:NERV)
www.nationaldailypress.com - September 15 at 9:49 AM
capitalcube.com logoMinerva Neurosciences, Inc. :NERV-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016 (NASDAQ:NERV)
www.capitalcube.com - September 14 at 10:38 AM
investornewswire.com logoMinerva Neurosciences, Inc (NASDAQ:NERV) Reported An Earnings Surprise Of 40 Percent - Investor Newswire (NASDAQ:NERV)
www.investornewswire.com - September 13 at 11:14 AM
News IconMinerva Neurosciences, Inc (NASDAQ:NERV): How Are Analysts Advising to Play This Stock? - Post News (NASDAQ:NERV)
www.kentuckypostnews.com - September 13 at 11:14 AM
News IconStock Struggling for the Quarter: Minerva Neurosciences, Inc. (NASDAQ:NERV) - Post News (NASDAQ:NERV)
www.kentuckypostnews.com - September 4 at 10:32 AM
News IconMinerva Neurosciences, Inc (NASDAQ:NERV): Brokerage Firm Consensus Update - Post News (NASDAQ:NERV)
www.kentuckypostnews.com - September 3 at 10:43 AM
globenewswire.com logoMinerva Neurosciences to Present at 23rd Annual NewsMakers in the Biotech Industry Conference on September 9 ... - GlobeNewswire (press release) (NASDAQ:NERV)
globenewswire.com - September 3 at 10:43 AM
finanznachrichten.de logoMINERVA NEUROSCIENCES INC (NASDAQ:NERV)
www.finanznachrichten.de - September 2 at 11:11 AM
finance.yahoo.com logoMinerva Neurosciences to Present at 23rd Annual NewsMakers in the Biotech Industry Conference on September 9, 2016 (NASDAQ:NERV)
finance.yahoo.com - September 2 at 11:11 AM
News IconStock Spotlight on Minerva Neurosciences, Inc (NASDAQ:NERV): Price Target & Estimates Update - Post News (NASDAQ:NERV)
www.kentuckypostnews.com - August 23 at 6:36 PM
investornewswire.com logoWill Minerva Neurosciences, Inc (NASDAQ:NERV) Hit $17 Price Target? - Investor Newswire (NASDAQ:NERV)
www.investornewswire.com - August 19 at 6:21 PM
News IconActive biotech company shares in the news: Minerva Neurosciences, Inc. (NASDAQ:NERV), Neuralstem, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:NERV)
voiceregistrar.com - August 19 at 6:21 PM
finance.yahoo.com logoWill Minerva Neurosciences (NERV) Continue to Surge Higher? (NASDAQ:NERV)
finance.yahoo.com - August 18 at 6:34 PM
finance.yahoo.com logoMINERVA NEUROSCIENCES, INC. Financials (NASDAQ:NERV)
finance.yahoo.com - August 11 at 6:51 PM
sbwire.com logoMarket Report, "Receptor Tyrosine Protein Kinase ERBB 4 - Pipeline Review, H1 2016", Published (NASDAQ:NERV)
www.sbwire.com - August 9 at 6:40 PM
finance.yahoo.com logoEdited Transcript of NERV earnings conference call or presentation 4-Aug-16 12:30pm GMT (NASDAQ:NERV)
finance.yahoo.com - August 7 at 10:34 AM
biz.yahoo.com logoMinerva Neurosciences Inc Earnings Call (Q2 2016) (NASDAQ:NERV)
biz.yahoo.com - August 4 at 9:37 AM
nasdaq.com logoMinerva Neurosciences Reports Second Quarter 2016 Financial Results and Business Updates (NASDAQ:NERV)
www.nasdaq.com - August 4 at 9:37 AM
twst.com logoMinerva Neurosciences Inc.: Minerva Neurosciences Reports Second Quarter 2016 Financial Results and Business Updates (NASDAQ:NERV)
www.twst.com - August 4 at 9:37 AM
sg.finance.yahoo.com logoMinerva Neurosciences reports 2Q loss (NASDAQ:NERV)
sg.finance.yahoo.com - August 4 at 9:37 AM
News IconBiotechnology Stocks on Investors' Radar -- Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma (NASDAQ:NERV)
www.kait8.com - August 2 at 11:16 AM
investornewswire.com logoCan Shares Of Minerva Neurosciences, Inc (NASDAQ:NERV) Hit $17? - Investor Newswire (NASDAQ:NERV)
www.investornewswire.com - July 29 at 9:26 AM
publicnow.com logoMinerva Neurosciences to Report Second Quarter 2016 Financial Results and Business Updates on August 4, 2016 (NASDAQ:NERV)
www.publicnow.com - July 28 at 8:48 AM
News IconMinerva Neurosciences Incorporated (NASDAQ:NERV) Short Interest Decreased By 5.62% - Consumer Eagle (NASDAQ:NERV)
www.consumereagle.com - July 21 at 6:41 PM
News IconA Reversal for Minerva Neurosciences Inc Is Not Near. The Stock Rises Again - Consumer Eagle (NASDAQ:NERV)
www.consumereagle.com - July 21 at 9:15 AM
News IconIs Minerva Neurosciences Inc a Sell? The Stock Declines Again - Press Telegraph (NASDAQ:NERV)
presstelegraph.com - July 15 at 11:12 AM
News IconInsiders Increasing Positions in: Minerva Neurosciences, Inc. (NASDAQ:NERV) - Press Telegraph (NASDAQ:NERV)
presstelegraph.com - July 14 at 10:01 AM
investornewswire.com logoStrong Sell Calls For Minerva Neurosciences, Inc (NASDAQ:NERV) At 0 - Investor Newswire (NASDAQ:NERV)
www.investornewswire.com - July 14 at 10:01 AM
news.cmlviz.com logoMinerva Neurosciences, Inc. Stock Momentum Hits Strength - CML News (NASDAQ:NERV)
news.cmlviz.com - July 8 at 6:30 PM
investornewswire.com logoMinerva Neurosciences, Inc (NASDAQ:NERV) Expected to Reach Highs Of $17 - Investor Newswire (NASDAQ:NERV)
www.investornewswire.com - July 7 at 9:20 AM
News IconWhat's Next for Minerva Neurosciences Inc After Today's Huge Increase? - Engelwood Daily (NASDAQ:NERV)
www.engelwooddaily.com - July 7 at 9:20 AM
News IconStock Tracking Down This Month; Investor Alert on Minerva Neurosciences, Inc. (NASDAQ:NERV) - Engelwood Daily (NASDAQ:NERV)
www.engelwooddaily.com - July 6 at 11:01 AM

Social

Minerva Neurosciences (NASDAQ:NERV) Chart for Friday, September, 30, 2016


Last Updated on 9/30/2016 by MarketBeat.com Staff